Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity

Cancer Immunology, Immunotherapy

Volumn 61, Issue 11, 2012, Pages 2055-2065

  Schettini, Jorge ^a   Kidiyoor, Amritha ^a   Besmer, Dahlia M ^a   Tinder, Teresa L ^a   Roy, Lopamudra Das ^a   Lustgarten, Joseph ^b   Gendler, Sandra J ^b   Mukherjee, Pinku ^a  

^a UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Cancer vaccines; Immune response to cancer; Immunoconjugates; Immunotherapy; Pancreatic cancer

Indexed keywords

ANTIBODY CONJUGATE; CPG OLIGODEOXYNUCLEOTIDE; HMFG 2 ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; MUCIN 1; MUCIN 1 ANTIBODY; MYELOID DIFFERENTIATION FACTOR 88; PERFORIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN ANTIBODY REACTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER MODEL; CELL IMMORTALIZATION; COCULTURE; CONTROLLED STUDY; CYTOLYSIS; FEMALE; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN DEPLETION; UPREGULATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CPG ISLANDS; FEMALE; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, NUDE; MICE, TRANSGENIC; MUCIN-1; MYELOID DIFFERENTIATION FACTOR 88; OLIGODEOXYRIBONUCLEOTIDES; PANCREATIC NEOPLASMS; PERFORIN; UP-REGULATION;

EID: 84871005809     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1264-y     Document Type: Article

References (44)

1. Weiner LM, Dhodapkar MV, Ferrone S (2009) Monoclonal antibodies for cancer immunotherapy. Lancet 373(9668):1033-1040
2. Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23(9):1147-1157
3. Cartron G et al (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99(3):754-758
4. Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21(21):3940-3947
5. Ravetch JV, Bolland S (2001) IgG Fc receptors. Annu Rev Immunol 19:275-290
6. Clynes RA et al (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6(4):443-446
7. Sulica A et al (2001) Ig-binding receptors on human NK cells as effector and regulatory surface molecules. Int Rev Immunol 20(3-4):371-414
8. Peipp M et al (2008) Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 112(6):2390-2399
9. Leidi M et al (2009) M2 macrophages phagocytose rituximabopsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol 182(7):4415-4422
10. Karagiannis SN et al (2007) IgE-antibody-dependent immunotherapy of solid tumors: Cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J Immunol 179(5):2832-2843
11. Khan KD et al (2006) A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Clin Cancer Res 12(23):7046-7053
12. Umana P et al (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17(2):176-180
13. Orange JS, Ballas ZK (2006) Natural killer cells in human health and disease. Clin Immunol 118(1):1-10
14. Bowles JA, Weiner GJ (2005) CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods 304(1-2):88-99
15. Fehniger TA, Caligiuri MA (2001) Interleukin 15: Biology and relevance to human disease. Blood 97(1):14-32
16. Moga E et al (2008) NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. Exp Hematol 36(1):69-77
17. Krieg AM (2006) Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5(6):471-484
18. Ballas ZK (2007) Modulation of NK cell activity by CpG oligodeoxynucleotides. Immunol Res 39(1-3):15-21
19. Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709-760
20. Roda JM, Parihar R, Carson WE III (2005) CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol 175(3):1619-1627
21. Krieg AM et al (2004) Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 27(6):460-471
22. Link BK et al (2006) Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother 29(5):558-568
23. Andoniou CE et al (2005) Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity. Nat Immunol 6(10):1011-1019
24. Adachi O et al (1998) Targeted disruption of the MyD88 gene results in loss of IL-1 and IL-18-mediated function. Immunity 9(1):143-150
25. Tinder TL et al (2008) MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J Immunol 181(5): 3116-3125
26. Mukherjee P et al (2009) Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J Immunol 182(1):216-224
27. Besmer DM et al (2011) Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis. Cancer Res 71(13):4432-4442
28. Roy LD et al (2011) MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene 30(12):1449-1459
29. Taylor-Papadimitriou J et al (1981) Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: Production and reaction with cells in culture. Int J Cancer 28(1):17-21
30. Grosso JF et al (2004) MUC1/sec-expressing tumors are rejected in vivo by a T cell-dependent mechanism and secrete high levels of CCL2. J Immunol 173(3):1721-1730
31. Vitetta ES, Hart DA, Forman J (1978) Relationship between trinitrophenol and H-2 antigens on trinitrophenyl-modified spleen cells. III. Quantitative aspects of trinitrophenol binding on cells treated with trinitrobenzene sulfonic acid. J Immunol 121(3): 997-1001
32. Trevani AS et al (2003) Bacterial DNA activates human neutrophils by a CpG-independent pathway. Eur J Immunol 33(11): 3164-3174
33. Sfondrini L et al (2002) Prevention of spontaneous mammary adenocarcinoma in HER-2/neu transgenic mice by foreign DNA. FASEB J 16(13):1749-1754
34. Sharma S et al (2008) Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALBneuT tolerant mice. Cancer Res 68(18):7530-7540
35. Zafir-Lavie I, Michaeli Y, Reiter Y (2007) Novel antibodies as anticancer agents. Oncogene 26(25):3714-3733
36. Sanjuan MA et al (2006) CpG-induced tyrosine phosphorylation occurs via a TLR9-independent mechanism and is required for cytokine secretion. J Cell Biol 172(7):1057-1068
37. Liese J, Schleicher U, Bogdan C (2007) TLR9 signaling is essential for the innate NK cell response in murine cutaneous leishmaniasis. Eur J Immunol 37(12):3424-3434
38. Krieg AM (2003) CpG motifs: The active ingredient in bacterial extracts? Nat Med 9(7):831-835
39. Zhu P et al (2009) Mechanism and regulatory function of CpG signaling via scavenger receptor B1 in primary B cells. J Biol Chem 284(34):22878-22887
40. Trieu A et al (2009) TLR9-independent effects of inhibitory oligonucleotides on macrophage responses to S. typhimurium. Immunol Cell Biol 87(3):218-225
41. Hokeness-Antonelli KL et al (2007) IFN-alphabeta-mediated inflammatory responses and antiviral defense in liver is TLR9-independent but MyD88-dependent during murine cytomegalovirus infection. J Immunol 179(9):6176-6183
42. Rutz M et al (2004) Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence-and pH-dependent manner. Eur J Immunol 34(9):2541-2550
43. Sivori S et al (2006) Comparison of different CpG oligodeoxynucleotide classes for their capability to stimulate human NK cells. Eur J Immunol 36(4):961-967
44. Lauzon NM, Mian F, Ashkar AA (2007) Toll-like receptors, natural killer cells and innate immunity. Adv Exp Med Biol 598:1-11